Genmab A/S Stock

Genmab A/S Capital Expenditures

The Capital Expenditures (CapEx) of Genmab A/S (GMAB.CO) as of Aug 13, 2026 is -55.00 M USD. In the previous year, Capital Expenditures (CapEx) was -44.09 M USD — a change of 24.74% (lower).

Capital Expenditures

-55.00 MUSD

YoY

24.74%

Last updated:

Capital Expenditures (CapEx) of Genmab A/S is 2026 -55.00 M USD. Capital Expenditures (CapEx) of Genmab A/S was 2025 -44.09 M USD. It decreases by 24.74% lower compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Capital Expenditures (CapEx) of Genmab A/S is -55.00 M USD in 2026.

Capital Expenditures (CapEx) of Genmab A/S changed from -44.09 M USD to -55.00 M USD, representing a 24.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Genmab A/S

All Key Metrics — Genmab A/S